玻璃体内注射Lucentis治疗中心性渗出性脉络膜视网膜病变的临床疗效

发布时间：2018-03-02 12:31

本文选题：脉络膜新生血管　切入点：中心性渗出性脉络膜视网膜病变　出处：《眼科新进展》2014年09期 　论文类型：期刊论文

【摘要】：目的评价玻璃体内注射Lucentis治疗中心性渗出性脉络膜视网膜病变(central exudative chorioretinopathy,CEC)的临床疗效。方法 CEC所致黄斑部脉络膜新生血管(choroidal neovascularization,CNV)患眼32例,对比分析单次玻璃体内注射Lucentis治疗前后最佳矫正视力(best corrected visual acuity,BCVA)、光学相干断层扫描(optical coherence tomography,OCT)及荧光素钠血管造影(fundus fluorescein angiography,FFA)的变化。结果玻璃体内注射Lucentis治疗前与治疗后1周、1个月和3个月BCVA分别为0.72±0.07、0.68±0.16、0.39±0.10、0.15±0.08;黄斑中心厚度(fovea centralis thickness,CMT)分别为(439.20±101.16)μm、(321.10±98.20)μm、(257.35±69.85)μm、(267.52±65.37)μm。玻璃体内注射Lucentis治疗后1周、1个月和3个月,BCVA显著提高,CMT显著降低,与治疗前相比差异均有显著统计学意义(均为P0.01);治疗后1个月、3个月分别与治疗后1周相比,BCVA显著提高,CMT显著降低,差异均有显著统计学意义(均为P0.01);治疗后1个月和3个月间相比,BCVA、CMT变化差异均无统计学意义(均为P0.05)。FFA检查显示:治疗后1周:CNV病灶渗漏停止或渗漏减少者21眼(65.63%),持续渗漏11眼(34.38%);治疗后1个月:CNV病灶渗漏停止或渗漏减少者28眼(87.50%),持续渗漏4眼(12.50%);治疗后3个月:CNV病灶渗漏停止或渗漏减少者27眼(84.38%),持续渗漏5眼(15.63%),1眼(3.13%)出现渗漏复发。结论玻璃体内注射Lucentis治疗可以在短期内部分或完全封闭CEC所致的CNV,减轻黄斑水肿、提高BCVA,为CEC的临床治疗提供了新的思路,但其长期效果有待进一步观察。
[Abstract]:Objective to evaluate the clinical effect of intravitreous injection of Lucentis in the treatment of central exudative chorioretinopathy. Methods 32 eyes with choroidal choroidal neovascularization caused by CEC were studied. The changes of best corrected visual acuteness, optical coherence tomography (Oct) and fundus fluorescein fluorescein angiography (FFAA) before and after single intravitreous injection of Lucentis were compared and analyzed. Results before and after Lucentis was injected into vitreous body. At 1 week, 1 month and 3 months, BCVA was 0.72 卤0.07 卤0.68 卤0.16 卤0.39 卤0.10 卤0.15 卤0.08, respectively. The thickness of fovea centralis thicknessnessus was 439.20 卤101.16 渭 m, respectively, 321.10 卤98.20 渭 m, 257.35 卤69.85 渭 m, 267.52 卤65.37 渭 m, respectively. There were significant differences between before and after treatment (all P 0.01), and the BCVA increased significantly in 1 month, 3 months after treatment and 1 week after treatment respectively. There was no significant difference in CMT between 1 month and 3 months after treatment (P 0.05). FFA examination showed that after 1 week of treatment, 21 eyes (65.63 eyes) had stopped or decreased leakage of 10% CNV lesions, and there was no significant difference in CMT between 1 month and 3 months after treatment (P 0.05). One month after treatment, 28 eyes (87.50 eyes) with persistent leakage stopped or decreased, 4 eyes (12.50%) with persistent leakage, 27 eyes (84.38%) with discontinuation of leakage or decreased leakage 3 months after treatment, 5 eyes (15.63 eyes) with continuous leakage and 3.13% (1 eye) with continuous leakage. Conclusion intravitreal injection of Lucentis can partially or completely block CEC in a short period of time and alleviate macular edema. The improvement of BCVA provides a new idea for the clinical treatment of CEC, but its long-term effect needs to be further observed.
【作者单位】：沈阳市第四人民医院眼科;
【分类号】：R774.1

【参考文献】